The highlight of FY17 was positive Phase II efficacy data from ReNeuron’s PISCES II clinical trial. As this and its other clinical programmes in ophthalmology and its earlier stage exosome platform progress, ReNeuron is entering a period of potentially significant milestones over the next 12 to 18 months. We maintain our valuation of £291m, adjusting for FY17 cash and rolling the model forward, which is offset by moving out the clinical timeline for the Phase III pivotal trial in
06 Jul 2017
Milestones expected as pipeline progresses
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Milestones expected as pipeline progresses
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
06 Jul 2017 -
Author:
Dr Linda Pomeroy -
Pages:
3
The highlight of FY17 was positive Phase II efficacy data from ReNeuron’s PISCES II clinical trial. As this and its other clinical programmes in ophthalmology and its earlier stage exosome platform progress, ReNeuron is entering a period of potentially significant milestones over the next 12 to 18 months. We maintain our valuation of £291m, adjusting for FY17 cash and rolling the model forward, which is offset by moving out the clinical timeline for the Phase III pivotal trial in